» Articles » PMID: 10229088

CpG-oligodeoxynucleotides Co-stimulate Primary T Cells in the Absence of Antigen-presenting Cells

Overview
Journal Eur J Immunol
Date 1999 May 6
PMID 10229088
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

CpG-containing oligodeoxynucleotides (CpG-ODN) act as powerful adjuvant during in vivo induction of T cell responses. While CpG-ODN directly activate antigen-presenting cells (APC) and thus exert an extrinsic activity on T cells, it is unclear whether they directly affect T cells (intrinsic activity). Here we analyze the effects of CpG-ODN on T cells in an APC-free cell culture. We report that CpG-ODN co-stimulate T cells provided they were triggered via their TCR. CpG-ODN induced IL-2 production, IL-2 receptor expression and thus proliferation. Proliferation was blocked by cyclosporin A or anti-IL-2 monoclonal antibodies (mAb) but not by anti-IL-4 mAb. Moreover, CpG-co-stimulated T cells differentiated into cytolytic T lymphocytes in vitro. Of note, IL-2-driven growth of primed T cells was not affected by CpG-ODN. Co-stimulation was also operative in T cells from CD28-/- mice and in TCR-transgenic T cells stimulated with peptide. CpG-ODN-mediated co-stimulation of T cells in vitro may thus explain part of the potent adjuvant effects of CpG-ODN in vivo.

Citing Articles

Innate Immune Sensors and Cell Death-Frontiers Coordinating Homeostasis, Immunity, and Inflammation in Skin.

Soe Y, Sim S, Kumari S Viruses. 2025; 17(2).

PMID: 40006996 PMC: 11861910. DOI: 10.3390/v17020241.


Rigid crosslinking of the CD3 complex leads to superior T cell stimulation.

Nelson A, Wang L, Laffey K, Becher L, Parks C, Hoffmann M Front Immunol. 2024; 15:1434463.

PMID: 39281668 PMC: 11392757. DOI: 10.3389/fimmu.2024.1434463.


Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection.

Du Y, Wu J, Liu J, Zheng X, Yang D, Lu M Front Immunol. 2022; 13:965018.

PMID: 35967443 PMC: 9372436. DOI: 10.3389/fimmu.2022.965018.


Lipid-Mediated Insertion of Toll-Like Receptor (TLR) Ligands for Facile Immune Cell Engineering.

Zhang M, Slaby E, Stephanie G, Yu C, Watts D, Liu H Front Immunol. 2020; 11:560.

PMID: 32425924 PMC: 7212467. DOI: 10.3389/fimmu.2020.00560.


Toll-like Receptors from the Perspective of Cancer Treatment.

Javaid N, Choi S Cancers (Basel). 2020; 12(2).

PMID: 32012718 PMC: 7072551. DOI: 10.3390/cancers12020297.